Pinion Immunotherapeutics Publishes Preclinical Data Supporting Clinical-Ready RNA Immunotherapy for HPV-16 Cervical Precancer
Pinion Immunotherapeutics has published preclinical data supporting ARV-2001, its lead RNA immunotherapy, in the peer-reviewed journal Vaccines. With an Investigational New Drug application cleared by the FDA, Pinion is ready to begin clinical development for women with HPV-16-positive high-grade cervical precancer (CIN2/3).
